BROX

Across TCGA pan-cancer cohorts, BROX mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BROX data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BROX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BROX expression acts as an unfavorable survival marker.

HNSC, LUAD, and LSCC are the cancer types where BROX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.328	0.889	.014	19	view →
LUAD	DFS	Quartile	II,III,IV	0.338	0.812	.008	9	view →
LSCC	OS	Median	All	0.814	0.900	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BROX–HNSC (DFS)

Open the HNSC breakdown →